Soleno Therapeutics, Inc.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a SLNO research report →
Companysoleno.life
Soleno Therapeutics, Inc. , a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Controlled-Release, a once-daily oral tablet for the treatment of Prader-Willi Syndrome, which is being evaluated in an ongoing Phase III clinical development program.
- CEO
- Anish Bhatnagar
- IPO
- 2014
- Employees
- 115
- HQ
- Redwood City, CA, US
Price Chart
Valuation
- Market Cap
- $2.76B
- P/E
- 28.75
- P/S
- 9.69
- P/B
- 5.57
- EV/EBITDA
- 25.68
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 98.63%
- Op Margin
- 30.80%
- Net Margin
- 33.70%
- ROE
- 22.86%
- ROIC
- 15.35%
Growth & Income
- Revenue
- $190.41M · 0.00%
- Net Income
- $20.89M · 111.88%
- EPS
- $0.41 · 109.36%
- Op Income
- $14.95M
- FCF YoY
- 167.41%
Performance & Tape
- 52W High
- $90.32
- 52W Low
- $29.43
- 50D MA
- $45.78
- 200D MA
- $51.16
- Beta
- -2.22
- Avg Volume
- 3.45M
Get TickerSpark's AI analysis on SLNO
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| May 18, 26 | Yen Kristen | sell | 37,639 |
| May 18, 26 | Yen Kristen | sell | 1,741 |
| May 18, 26 | Yen Kristen | sell | 4,999 |
| May 18, 26 | Yen Kristen | sell | 4,000 |
| May 18, 26 | Yen Kristen | sell | 666 |
| May 18, 26 | Yen Kristen | sell | 18,800 |
| May 18, 26 | Yen Kristen | sell | 2,445 |
| May 18, 26 | Yen Kristen | sell | 11,667 |
| May 18, 26 | Yen Kristen | sell | 55,392 |
| May 18, 26 | Yen Kristen | sell | 16,000 |
Our SLNO Coverage
We haven't published any research on SLNO yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate SLNO Report →